ATE322286T1 - Regulierung der systemischen immunantworten mittels zytokinen und antigenen - Google Patents

Regulierung der systemischen immunantworten mittels zytokinen und antigenen

Info

Publication number
ATE322286T1
ATE322286T1 AT02002123T AT02002123T ATE322286T1 AT E322286 T1 ATE322286 T1 AT E322286T1 AT 02002123 T AT02002123 T AT 02002123T AT 02002123 T AT02002123 T AT 02002123T AT E322286 T1 ATE322286 T1 AT E322286T1
Authority
AT
Austria
Prior art keywords
systemic immune
antigen
antigens
immune response
cytokines
Prior art date
Application number
AT02002123T
Other languages
English (en)
Inventor
Glenn Dranoff
Richard Mulligan
Drew Pardoll
Original Assignee
Whitehead Biomedical Inst
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25091012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322286(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Whitehead Biomedical Inst, Univ Johns Hopkins Med filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE322286T1 publication Critical patent/ATE322286T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02002123T 1991-10-04 1992-10-05 Regulierung der systemischen immunantworten mittels zytokinen und antigenen ATE322286T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77119491A 1991-10-04 1991-10-04

Publications (1)

Publication Number Publication Date
ATE322286T1 true ATE322286T1 (de) 2006-04-15

Family

ID=25091012

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02002123T ATE322286T1 (de) 1991-10-04 1992-10-05 Regulierung der systemischen immunantworten mittels zytokinen und antigenen
AT92921896T ATE230615T1 (de) 1991-10-04 1992-10-05 Regulierung der systemischen immunantworten mittels zytokinen und antigenen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92921896T ATE230615T1 (de) 1991-10-04 1992-10-05 Regulierung der systemischen immunantworten mittels zytokinen und antigenen

Country Status (8)

Country Link
EP (2) EP0607309B1 (de)
JP (1) JP3580371B2 (de)
AT (2) ATE322286T1 (de)
AU (1) AU677165B2 (de)
CA (1) CA2120503C (de)
DE (2) DE69233614T2 (de)
ES (1) ES2189788T3 (de)
WO (1) WO1993006867A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5902576A (en) * 1992-10-22 1999-05-11 Yeda Research And Development Co. Ltd. At Weizmann Institute Of Science Antitumor pharmaceutical composition comprising IL-6 transfected cells
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
CA2178902A1 (en) * 1993-12-14 1995-06-22 Drew Pardoll Controlled release of pharmaceutically active substances for immunotherapy
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
JPH10512242A (ja) * 1994-12-30 1998-11-24 カイロン コーポレイション 組み合わせ遺伝子送達ビヒクル
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
EP0835130A1 (de) * 1995-06-19 1998-04-15 University Of Medicine & Dentistry Of New Jersey Gentherapie von soliden tumoren mit interferone allein oder mit anderen immunoeffektoren proteinen
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
JP2001517206A (ja) 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
EP0834323A1 (de) * 1996-09-30 1998-04-08 Introgene B.V. Cytokin-Gentherapie für die Behandlung von malignen Tumoren
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
JP2006507214A (ja) * 2002-02-22 2006-03-02 イントラセル・リソーシーズ・エル・エル・シー 無菌の、免疫原性の、非腫瘍形成性の腫瘍細胞組成物及び方法
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
EP1699480B1 (de) 2003-12-30 2011-06-15 Mologen AG Allogenes tumortherapeutikum

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303687B1 (de) * 1987-03-02 1992-11-11 Genetics Institute, Inc. Zubereitungen zur verbesserung der adcc-therapien
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE3806565A1 (de) * 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
DE69114299T3 (de) * 1990-09-14 2005-09-15 The Johns Hopkins University Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems.
AU656544B2 (en) * 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells

Also Published As

Publication number Publication date
DE69233614D1 (de) 2006-05-18
DE69233614T2 (de) 2007-02-15
DE69232890T2 (de) 2003-10-09
ES2189788T3 (es) 2003-07-16
CA2120503C (en) 2006-04-04
WO1993006867A1 (en) 1993-04-15
EP0607309A1 (de) 1994-07-27
ATE230615T1 (de) 2003-01-15
AU2777692A (en) 1993-05-03
JP3580371B2 (ja) 2004-10-20
DE69232890D1 (de) 2003-02-13
EP0607309B1 (de) 2003-01-08
EP1216710B1 (de) 2006-04-05
EP1216710A1 (de) 2002-06-26
AU677165B2 (en) 1997-04-17
CA2120503A1 (en) 1993-04-15
JPH07502987A (ja) 1995-03-30

Similar Documents

Publication Publication Date Title
ATE230615T1 (de) Regulierung der systemischen immunantworten mittels zytokinen und antigenen
FI920132A0 (fi) Stabila vaccinkompositioner innehaollande interleukiner.
ATE320435T1 (de) Oxazolo-, thiazolo- und selenazolo-(4,5- c)naphthyridin-4-amine und analoge davon
NO970993L (no) Mutant enterotoksin som er effektiv som en ikke-toksisk oral adjuvant
ES2092306T3 (es) Adyuvante para vacunas.
NO941422D0 (no) Nytt cytokin
DE69033143D1 (de) Cytokinsynthesehemmender faktor (csif) und verfahren zur anwendung
ATE73321T1 (de) Zusammensetzung mit verzoegerter abgabe.
FI851859A0 (fi) Antigenpreparat och isolering av saodana preparat.
DE68915165D1 (de) Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
WO2001039803A3 (en) Interleukin-1 muteins useful as vaccine adjuvants
DE69919984D1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
IT8049162A0 (it) Belli poltrone e simili dispositivo per trasmissione aerea di impulsi ultrasuonici atto alla regolazione della posizione di sga
ES2082201T3 (es) Uso de il-4 para mejorar la respuesta inmune a las pruebas de antigenos infecciosos.
DE3867220D1 (de) Gasleit der schalldaempfungseinrichtung fuer drehkolbenverdichter.
ITMI920879A1 (it) Determinazione della velocita' di volo reale di missili
EP0351876A3 (de) Zusammensetzung zur Steigerung der Impfungswirkung
NO922304D0 (no) Eliminering av aktiverte lymfocytter
DE3675995D1 (de) Mittel mit kontinuierlicher freisetzung von phenylethanolaminderivaten.
DE60042827D1 (de) Cytokine aus säugetieren und dazugehörende reagenzien
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
ATE60765T1 (de) Pyranderivate.
FI812774L (fi) Foerfarande foer framstaellning av n-4-/(2,4-diamino-6-pteridinyl)-metyl/metylamino/benzoyl/glutaminsyra
ES254408Y (es) Dispositivo para la prolongacion de asientos de sillones y similares

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties